A phase II/III randomized, multicenter trial of prednisone/sirolimus <i>versus</i> prednisone/ sirolimus/calcineurin inhibitor for the treatment of chronic graft-<i>versus</i>-host disease: BMT CTN 0801

Paul A. Carpenter(Fred Hutch Cancer Center), Mukta Arora(Fairview Health Services), Aleksandr Lazaryan(Moffitt Cancer Center), Edmund K. Waller(Emory University), Brent R. Logan(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Corey Cutler(Harvard University), Stephanie J. Lee(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Amin M. Alousi(McGill University), Eneida R. Nemecek(Oregon Health & Science University), Laura Johnston(Stanford Medicine), Jiaxi Zhu(Emmes (United States)), Adam Mendizabal(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Steven Z. Pavletic(National Institutes of Health), Carrie L. Kitko(Vanderbilt University Medical Center), Daniel J. Weisdorf(University of Minnesota), Stefanie Sarantopoulos(Duke University), Sunil Abhyankar(University of Kansas Medical Center), Mary M. Horowitz(Medical College of Wisconsin), Juan Wu(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Javier Bolaños‐Meade(Johns Hopkins University), Kelly O’Brien(Emmes (United States)), Luciano J. Costa(University of Alabama at Birmingham)
Haematologica
June 28, 2018
Cited by 55


Related Papers